Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adaptive Biotechnologies Corp
(NQ:
ADPT
)
4.700
+0.030 (+0.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptive Biotechnologies Corp
< Previous
1
2
3
4
5
Next >
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
December 21, 2022
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical...
Via
Benzinga
What To Know About Piper Sandler's Upgrade of Adaptive Biotechnologies
December 21, 2022
Via
Benzinga
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
December 21, 2022
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Looking Into Adaptive Biotechnologies's Return On Capital Employed
November 25, 2022
Via
Benzinga
Expert Ratings for Adaptive Biotechnologies
November 07, 2022
Adaptive Biotechnologies (NASDAQ:ADPT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
August 11, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
December 21, 2022
Via
Benzinga
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
December 10, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues
February 16, 2022
Adaptive Biotechnologies Corp (NASDAQ: ADPT)
Via
Benzinga
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
December 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
December 01, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
November 21, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
November 21, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
Gainers
Via
Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
November 11, 2022
Gainers
Via
Benzinga
5 Top Stocks Cathie Wood Is Buying This Week
November 04, 2022
Cathie Wood just lauded Elon Musk's acquisition of Twitter, believing the platform will become a "super-app." Here are her top five buys.
Via
InvestorPlace
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
General Electric To Surge Around 27%? Plus This Analyst Predicts $44 For General Motors
October 26, 2022
RBC Capital raised the price target on General Electric Company (NYSE: GE) from $81 to $93. General Electric shares fell 0.5% to close at $73.00 on Tuesday.
Via
Benzinga
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
October 11, 2022
Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQ
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
October 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
August 25, 2022
Upgrades
Via
Benzinga
Adaptive Biotechnologies: Q2 Earnings Insights
August 03, 2022
Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Outlook For Adaptive Biotechnologies
August 02, 2022
Adaptive Biotechnologies (NASDAQ:ADPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Why Adaptive Biotechnologies Shares Are Rising
June 15, 2022
Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
June 03, 2022
Via
Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
May 23, 2022
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 23, 2022
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2...
Via
Benzinga
Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO
March 09, 2022
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's...
Via
Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
February 16, 2022
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36...
Via
Benzinga
Recap: Adaptive Biotechnologies Q4 Earnings
February 15, 2022
Adaptive Biotechnologies (NASDAQ:ADPT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.